Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

81.83USD
4:00pm EDT
Change (% chg)

$-0.75 (-0.91%)
Prev Close
$82.58
Open
$82.12
Day's High
$82.81
Day's Low
$81.37
Volume
1,320,745
Avg. Vol
1,874,167
52-wk High
$139.70
52-wk Low
$74.14

Latest Key Developments (Source: Significant Developments)

Oncomed Provides Update On Navicixizumab Partnership
Thursday, 20 Sep 2018 08:00am EDT 

Sept 20 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED PROVIDES UPDATE ON NAVICIXIZUMAB PARTNERSHIP.ONCOMED PHARMACEUTICALS - CELGENE NOTIFIED CO IT DECIDED NOT TO EXERCISE ITS OPTION TO LICENSE CO'S BISPECIFIC ANTIBODY NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED AND CELGENE ARE WORKING TO FORMALIZE TERMINATION OF COLLABORATION AGREEMENT WITH RESPECT TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS - CELGENE CONTINUES TO RETAIN ITS OPTIONS TO LICENSE ONCOMED'S ETIGILIMAB UNDER COLLABORATION.ONCOMED PHARMACEUTICALS INC - EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.  Full Article

Evotec, Celgene Partner On Targeted Protein Degradation
Thursday, 6 Sep 2018 01:00am EDT 

Sept 6 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND CELGENE ENTER PARTNERSHIP IN THE FIELD OF TARGETED PROTEIN DEGRADATION.SAYS FINANCIALS INCLUDE UPFRONT PAYMENT AS WELL AS SIGNIFICANT POTENTIAL MILESTONE-BASED PAYMENTS AND ROYALTIE.  Full Article

Celgene Q2 Earnings Per Share $1.43
Thursday, 26 Jul 2018 07:30am EDT 

July 26 (Reuters) - Celgene Corp ::CELGENE REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS.Q2 REVENUE $3.814 BILLION VERSUS I/B/E/S VIEW $3.7 BILLION.Q2 EARNINGS PER SHARE $1.43.Q2 EARNINGS PER SHARE VIEW $2.11 -- THOMSON REUTERS I/B/E/S.RAISING FULL-YEAR TOTAL REVENUE GUIDANCE TO ABOUT $15 BILLION AND REVLIMID NET SALES TO ABOUT $9.7 BILLION.QTRLY ADJUSTED EARNINGS PER SHARE $2.16.REVLIMID SALES FOR Q2 INCREASED 21 PERCENT TO $2,453 MILLION.OTEZLA SALES FOR Q2 WERE $375 MILLION, A 5 PERCENT INCREASE YEAR-OVER-YEAR.SEES 2018 EARNINGS PER SHARE $5.95-$6.25.SEES 2018 ADJUSTED DILUTED EPS IN RANGE OF $8.70- $8.75.FY2018 EARNINGS PER SHARE VIEW $8.52, REVENUE VIEW $14.93 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Celgene Meets Main Goal In Study Of Revlimid In Combination With Rituximab
Monday, 23 Jul 2018 04:30pm EDT 

July 23 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES PHASE III ‘AUGMENT’ STUDY OF REVLIMID® IN COMBINATION WITH RITUXIMAB (R2) FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY INDOLENT LYMPHOMA MET PRIMARY ENDPOINT.CELGENE - FINAL ANALYSIS SHOWED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL FOR R2 COMPARED WITH RITUXIMAB PLUS PLACEBO.CELGENE CORP - DATA FROM AUGMENT WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING & CO PLANS TO PREPARE GLOBAL REGULATORY SUBMISSIONS IN Q1 OF 2019.CELGENE CORP - A FAVORABLE TREND WAS OBSERVED FOR OVERALL SURVIVAL (OS) DURING THE ANALYSIS.CELGENE CORP - FOLLOW-UP WILL CONTINUE FOR THE MATURE OS RESULTS.CELGENE - REVLIMID CAN LEAD TO EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, AND VENOUS AND ARTERIAL THROMBOEMBOLISM.  Full Article

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 04:05pm EDT 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Beigene Announces Approval Of Revlimid In China
Tuesday, 27 Feb 2018 06:00pm EST 

Feb 27 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES APPROVAL OF REVLIMID® FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA.BEIGENE LTD - ‍REVLIMID HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF MULTIPLE MYELOMA​.  Full Article

FDA rejects filing for Celgene MS drug
Tuesday, 27 Feb 2018 04:30pm EST 

Feb 27 (Reuters) - Celgene Corp ::CELGENE PROVIDES REGULATORY UPDATE ON OZANIMOD FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS.CELGENE CORP - ‍FDA DETERMINED NONCLINICAL AND CLINICAL PHARMACOLOGY SECTIONS IN NDA WERE INSUFFICIENT TO PERMIT A COMPLETE REVIEW​.CELGENE - CO INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA.CELGENE - GOT REFUSAL TO FILE LETTER FROM FDA ABOUT CO'S NDA FOR OZANIMOD IN DEVELOPMENT FOR TREATING PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.CELGENE - ‍SEEKING GUIDANCE WHICH INCLUDES REQUESTING MEETING WITH FDA, TO ASCERTAIN WHAT ADDITIONAL DATA WILL BE REQUIRED TO RESUBMIT NDA​.  Full Article

Celgene Receives Antitrust Clearance For Juno Acquisition
Wednesday, 21 Feb 2018 07:30am EST 

Feb 21 (Reuters) - Celgene Corp ::CELGENE RECEIVES ANTITRUST CLEARANCE FOR JUNO ACQUISITION.CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​.  Full Article

Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients
Thursday, 15 Feb 2018 09:30am EST 

Feb 15 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS.CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​.CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​.  Full Article

Celgene Announces Additional $5 Billion Share Repurchase Authorization
Wednesday, 14 Feb 2018 07:30am EST 

Feb 14 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE CORP - ‍OPEN-ENDED PROGRAM IS EFFECTIVE IMMEDIATELY​.  Full Article

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.